Hermanth Varghese
President bij VENUS CONCEPT INC.
Vermogen: 14 167 $ op 29-02-2024
Profiel
Hermanth Jacob Varghese holds the position of President & Chief Operating Officer at Venus Concept, Inc.
In his past career he occupied the position of Senior Vice President-Strategy & Operations at HLS Therapeutics, Inc., Executive VP-Corporate Development & Strategy at Endo International Plc, Senior VP-Corporate Development at Bausch Health Cos., Inc. Vice President-Business Development for Biovail Corp.
and General Manager for Bausch + Lomb Corp.
(both are subsidiaries of Bausch Health Cos., Inc.), Assistant Vice President at MedTech Partners, Inc. and Assistant Vice President at Medical Discovery Management Corp.
He received a doctorate and an undergraduate degree from the University of Western Ontario.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
VENUS CONCEPT INC
0.26% | 24-03-2023 | 16 667 ( 0.26% ) | 14 167 $ | 29-02-2024 |
Actieve functies van Hermanth Varghese
Bedrijven | Functie | Begin |
---|---|---|
VENUS CONCEPT INC. | President | 17-10-2022 |
Eerdere bekende functies van Hermanth Varghese
Bedrijven | Functie | Einde |
---|---|---|
HLS THERAPEUTICS INC. | Chief Operating Officer | 01-01-2022 |
ENDO INTERNATIONAL PLC | Corporate Officer/Principal | 31-12-2016 |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Director/Board Member | 06-06-2014 |
BAUSCH + LOMB CORPORATION | Corporate Officer/Principal | 01-01-2014 |
BAUSCH HEALTH COMPANIES INC. | Corporate Officer/Principal | 01-01-2014 |
Opleiding van Hermanth Varghese
University of Western Ontario | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 4 |
---|---|
ENDO INTERNATIONAL PLC | Health Technology |
BAUSCH HEALTH COMPANIES INC. | Health Technology |
HLS THERAPEUTICS INC. | Health Technology |
BAUSCH + LOMB CORPORATION | Health Technology |
Bedrijven in privébezit | 6 |
---|---|
Biovail Corp.
Biovail Corp. Pharmaceuticals: MajorHealth Technology Biovail Corp. develops and manufactures pharmaceutical products. The company provides different types of products which include Wellbutrin SR, Retavase, Zyban and Tiazac XC in Canada and Zovirax Ointment and Zovirax Cream in the United States. Its products are used for cardiovascular disease, central nervous system disorders, pain management and other niche areas. It was founded on March 29, 1994 and is headquartered in Mississauga, Canada. | Health Technology |
MedTech Partners, Inc.
MedTech Partners, Inc. Investment ManagersFinance MedTech Partners, Inc. provides investment services. The firm offers investment services to develop and commercialize early-stage biomedical innovations. The company is headquartered in Nepean, Ontario. | Finance |
Trillium Therapeutics, Inc. /Old/
Trillium Therapeutics, Inc. /Old/ Miscellaneous Commercial ServicesCommercial Services Trillium Therapeutics Inc. (TTI), is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of immune-mediated disorders. The Company's therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant or harmful immune responses, such as autoimmune disease, inflammatory disorders, and cancer. TTI's objective is to create a broad and innovative pipeline of proprietary biologic product opportunities, as part of its overall strategy of building and solidifying its reputation as a premier R & D company. The company's business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and proof-of-principle in man. The company has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own. TTI has five scientific programs at various stages of preclinical testing. Two of its programs focus on the immunoregulatory protein CD200 and its receptor, a third targets the activating Fc receptor Fc RIIa (CD32a) and the final two involve the use of a growth factor in the prevention of necrotizing enterocolitis and the treatment of interstitial cystitis. | Commercial Services |
Medical Discovery Management Corp.
Medical Discovery Management Corp. Investment ManagersFinance Medical Discovery Management Corp. (MDMC) is a venture capital fund manager located in Toronto. They are a subsidiary of JovFunds Management, Inc. Their ultimate parent is Jovian Capital Corp. (Toronto: JOV.TO) | Finance |
Venus Concept, Inc. | |
Litha Healthcare Group Ltd.
Litha Healthcare Group Ltd. BiotechnologyHealth Technology Litha Healthcare Group Ltd. develops pharmaceutical products and medical devices. The firm distributes products in three main sectors of the South African healthcare industry. It operates through following divisions; Litha Pharma, Medical and Biotech. The company was founded by Selwyn Kahanovitz in 1992 and is headquartered in Johannesburg, South Africa. | Health Technology |